樂
樂觀
樂觀 · 25%VSA
$1.95
情境價格
$2.350
+1.236 (+52.60%)收盤時
Loading chart…
- 最高
- 2.350
- 開盤
- 1.990
- 成交量加權均價
- 2.17
- 成交量
- 29.80M
- 市值
- —
- 最低
- 1.800
- 成交金額
- 64.57M
- 企業價值/稅息折舊攤銷前利潤（TTM）
- 0.00
VisionSys AI Inc is a holding company primarily engaged in the development of brain-computer interface (BCI) technologies and related businesses. The Company's main business is developing, procuring, selling, and distributing BCI-enabled or BCI-adjacent products and solutions, and to provide related technical services. The BCI technologies are used in medical and healthcare-related applications, including functional rehabilitation, communication support, neurological disease-related monitoring and intervention, sensory assistance, and general wellness management. The Company mainly operates its businesses in the domestic market.
AI 分析 of VisionSys AI Inc (VSA)
賣出Given the current price of $1.62, the stock has dropped 93.41% year-to-date and is trading near its 52-week low of $1.56. The RSI is at 28.371, indicating that the stock is oversold, but the forward P/E ratio of 23.4742 suggests high future earnings expectations that may not be met, especially with a significant projected net margin loss of -3853.03% in Q4 2025. The main risk is the company's extremely low current ratio of 0.05, indicating potential liquidity issues.
估值指標
VisionSys AI Inc（VSA）目前預期本益比為 23.47，5 年平均預期本益比為 8.69。
Alphio AI 對 VSA 的價格情境
情境價格取自當年最後一個月度預測區間。機率為固定的模型權重（25 / 50 / 25），不構成保證。
事件時間軸
資訊
8.505-05seekingalphaVisionSys AI Announces 1-for-10 ADS Reverse Split Plan
- 8.505-05seekingalpha
VisionSys AI Announces Reverse ADS Split Plan
8.503-27NewsfilterVisionSys AI Inc. Secures $3 Million in Direct Offering
9.503-12BenzingaPetco Reports Strong Q4 Results, Shares Surge
8.512-18GlobenewswireVisionSys AI Inc (VSA) Executes 1-for-50 Reverse Stock Split, Reducing Shares to Approximately 554 Million
VSA 常見問題 —— 由 Alphio AI 解答
VisionSys AI Inc is a holding company primarily engaged in the development of brain-computer interface (BCI) technologies and related businesses. The Company's main business is developing, procuring, selling, and distributing BCI-enabled or BCI-adjacent products and solutions, and to provide related technical services. The BCI technologies are used in medical and healthcare-related applications, including functional rehabilitation, communication support, neurological disease-related monitoring and intervention, sensory assistance, and general wellness management. The Company mainly operates its businesses in the domestic market. It operates in the Healthcare sector.
Given the current price of $1.62, the stock has dropped 93.41% year-to-date and is trading near its 52-week low of $1.56. The RSI is at 28.371, indicating that the stock is oversold, but the forward P/E ratio of 23.4742 suggests high future earnings expectations that may not be met, especially with a significant projected net margin loss of -3853.03% in Q4 2025. The main risk is the company's extremely low current ratio of 0.05, indicating potential liquidity issues.
社群
更多 ↗暫無貼文
註冊或登入後參與討論相關文章
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。